These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37957680)

  • 1. SMARTERscreen protocol: a three-arm cluster randomised controlled trial of patient SMS messaging in general practice to increase participation in the Australian National Bowel Cancer Screening Program.
    McIntosh JG; Emery JD; Wood A; Chondros P; Goodwin BC; Trevena J; Wilson C; Chang S; Hocking J; Campbell T; Macrae F; Milley K; Lew JB; Nightingale C; Dixon I; Castelli M; Lee N; Innes L; Jolley T; Fletcher S; Buchanan L; Doncovio S; Broun K; Austin G; Jiang J; Jenkins MA
    Trials; 2023 Nov; 24(1):723. PubMed ID: 37957680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing bowel cancer screening using SMS in general practice: the SMARTscreen cluster randomised trial.
    McIntosh JG; Jenkins M; Wood A; Chondros P; Campbell T; Wenkart E; O'Reilly C; Dixon I; Toner J; Martinez-Gutierrez J; Govan L; Emery JD
    Br J Gen Pract; 2024 Apr; 74(741):e275-e282. PubMed ID: 38164588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SMARTscreen Trial: a randomised controlled trial investigating the efficacy of a GP-endorsed narrative SMS to increase participation in the Australian National Bowel Cancer Screening Program.
    Wood A; Emery JD; Jenkins M; Chondros P; Campbell T; Wenkart E; O'Reilly C; Cowie T; Dixon I; Toner J; Khalajzadeh H; Gutierrez JM; Govan L; Buckle G; McIntosh JG
    Trials; 2022 Jan; 23(1):31. PubMed ID: 35022080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.
    Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K
    PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
    Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
    Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of a risk assessment and decision support tool (CRISP) compared with usual care in general practice to increase risk-stratified colorectal cancer screening: study protocol for a randomised controlled trial.
    Walker JG; Macrae F; Winship I; Oberoi J; Saya S; Milton S; Bickerstaffe A; Dowty JG; De Abreu Lourenço R; Clark M; Galloway L; Fishman G; Walter FM; Flander L; Chondros P; Ait Ouakrim D; Pirotta M; Trevena L; Jenkins MA; Emery JD
    Trials; 2018 Jul; 19(1):397. PubMed ID: 30045764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SCRIPT trial: study protocol for a randomised controlled trial of a polygenic risk score to tailor colorectal cancer screening in primary care.
    Saya S; Boyd L; Chondros P; McNamara M; King M; Milton S; Lourenco RA; Clark M; Fishman G; Marker J; Ostroff C; Allman R; Walter FM; Buchanan D; Winship I; McIntosh J; Macrae F; Jenkins M; Emery J
    Trials; 2022 Sep; 23(1):810. PubMed ID: 36163034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing the Effectiveness of a Primary Care Intervention to Improve Uptake of Colorectal Cancer Screening: A Randomized Controlled Trial Protocol.
    Dodd N; Carey ML; Mansfield E; Oldmeadow C
    JMIR Res Protoc; 2017 May; 6(5):e86. PubMed ID: 28490420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colonoscopies in Australia - how much does the National Bowel Cancer Screening Program contribute to colonoscopy use?
    Worthington J; He E; Lew JB; St John J; Horn C; Grogan P; Canfell K; Feletto E
    Public Health Res Pract; 2023 Mar; 33(1):. PubMed ID: 36477980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of mailed invitation strategies to improve fecal occult blood test participation in men: protocol for a randomized controlled trial.
    Duncan A; Zajac I; Flight I; Stewart BJ; Wilson C; Turnbull D
    Trials; 2013 Jul; 14():239. PubMed ID: 23902589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with participation in colorectal cancer screening in Australia: Results from the 45 and Up Study cohort.
    He E; Lew JB; Egger S; Banks E; Ward RL; Beral V; Canfell K
    Prev Med; 2018 Jan; 106():185-193. PubMed ID: 29109015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Text messaging as a tool to improve cancer screening programs (M-TICS Study): A randomized controlled trial protocol.
    Vives N; Farre A; Ibáñez-Sanz G; Vidal C; Binefa G; Milà N; Pérez-Lacasta MJ; Travier N; Benito L; Espinàs JA; Bagaria G; Garcia M
    PLoS One; 2021; 16(1):e0245806. PubMed ID: 33481914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
    Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the effectiveness of GP endorsement on increasing participation in the NHS Bowel Cancer Screening Programme in England: study protocol for a randomized controlled trial.
    Damery S; Smith S; Clements A; Holder R; Nichols L; Draper H; Clifford S; Parker L; Hobbs R; Wilson S
    Trials; 2012 Feb; 13():18. PubMed ID: 22348399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential for tailored screening to reduce bowel cancer mortality for Aboriginal and Torres Strait Islander peoples in Australia: Modelling study.
    Lew JB; Feletto E; Worthington J; Roder D; Canuto K; Miller C; D'Onise K; Canfell K
    J Cancer Policy; 2022 Jun; 32():100325. PubMed ID: 35560263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
    Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D
    PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing bowel cancer screening participation: integrating population-wide, primary care and more targeted approaches.
    Lofti-Jam KL; O'Reilly CL; Feng CS; Wakefield MA; Durkin S; Broun KH
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
    Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
    Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.